A Phase II Trial of GT103 in Combination With Pembrolizumab in STK11 Mutant Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new combination treatment for patients with advanced lung cancer that has a specific genetic change called an STK11 mutation. Researchers want to see if adding a new drug, GT103, to the existing immunotherapy medicine pembrolizumab helps the immune system better fight cancer cells.
You may be eligible if you are 18 or older, can manage daily tasks independently, and have confirmed STK11-mutated lung cancer that has grown despite previous immunotherapy. There are specific requirements regarding your recent treatment history and overall health to ensure your safety.
Participants will receive the combined treatment of GT103 and pembrolizumab. Throughout the study, you will have regular check-ups that include blood tests, imaging scans like CTs or MRIs, and heart function tests to monitor how you and your cancer are responding to the therapy.
The study is currently recruiting new participants and is located in Buffalo, New York.
- 1The study tests a new drug combination meant to help the immune system attack cancer more effectively.
- 2Participation requires a specific STK11 genetic mutation confirmed by a laboratory test.
- 3Safety is a top priority, and your health will be closely monitored with regular scans and tests throughout the trial.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.